Compare Stocks: ARCT, RARE, IMCR, and MAZE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$12.03 -4.6%	$13.00	$5.50 ▼ $24.17	$358.42M	2.48	821,396 shs	464,148 shs
IMCR Immunocore	$27.82 -4.2%	$33.39	$27.56 ▼ $40.71	$1.50B	0.81	440,740 shs	904,453 shs
MAZE Maze Therapeutics	$26.66 -3.8%	$26.84	$21.95 ▼ $53.65	$1.54B	2.16	945,972 shs	615,138 shs
RARE Ultragenyx Pharmaceutical	$14.92 -2.5%	$19.46	$12.73 ▼ $39.89	$1.51B	0.35	5.53 million shs	5.30 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	-4.60%	-7.46%	-18.33%	+88.26%	-37.96%
IMCR Immunocore	-4.20%	-5.85%	-14.66%	-19.78%	-14.00%
MAZE Maze Therapeutics	-3.75%	+0.87%	+8.37%	-9.29%	-6.69%
RARE Ultragenyx Pharmaceutical	-2.48%	+3.18%	+4.34%	-52.95%	-53.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$12.03 -4.6%	$13.00	$5.50 ▼ $24.17	$358.42M	2.48	821,396 shs	464,148 shs
IMCR Immunocore	$27.82 -4.2%	$33.39	$27.56 ▼ $40.71	$1.50B	0.81	440,740 shs	904,453 shs
MAZE Maze Therapeutics	$26.66 -3.8%	$26.84	$21.95 ▼ $53.65	$1.54B	2.16	945,972 shs	615,138 shs
RARE Ultragenyx Pharmaceutical	$14.92 -2.5%	$19.46	$12.73 ▼ $39.89	$1.51B	0.35	5.53 million shs	5.30 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	-4.60%	-7.46%	-18.33%	+88.26%	-37.96%
IMCR Immunocore	-4.20%	-5.85%	-14.66%	-19.78%	-14.00%
MAZE Maze Therapeutics	-3.75%	+0.87%	+8.37%	-9.29%	-6.69%
RARE Ultragenyx Pharmaceutical	-2.48%	+3.18%	+4.34%	-52.95%	-53.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	2.67	Moderate Buy	$22.00	82.88% Upside
IMCR Immunocore	2.58	Moderate Buy	$56.38	102.64% Upside
MAZE Maze Therapeutics	3.08	Buy	$63.40	137.81% Upside
RARE Ultragenyx Pharmaceutical	2.48	Hold	$34.58	131.76% Upside

Current Analyst Ratings Breakdown

Latest ARCT, RARE, IMCR, and MAZE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	ARCT Arcturus Therapeutics	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$13.00 ➝ $19.00
10/6/2026	RARE Ultragenyx Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/24/2026	ARCT Arcturus Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
9/24/2026	ARCT Arcturus Therapeutics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$23.00 ➝ $20.00
9/24/2026	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Buy	$8.00 ➝ $20.00
9/24/2026	MAZE Maze Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$110.00
9/23/2026	MAZE Maze Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$50.00
9/23/2026	MAZE Maze Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$50.00
9/23/2026	MAZE Maze Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$48.00
9/23/2026	RARE Ultragenyx Pharmaceutical	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
9/22/2026	MAZE Maze Therapeutics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$46.00

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$82.03M	4.17	N/A	N/A	$7.53 per share	1.60
IMCR Immunocore	$400.02M	3.58	N/A	N/A	$7.52 per share	3.70
MAZE Maze Therapeutics	$167.50M	8.84	N/A	N/A	$7.38 per share	3.61
RARE Ultragenyx Pharmaceutical	$673M	2.19	N/A	N/A	($0.83) per share	-17.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$65.78M	-$3.31	N/A	N/A	N/A	-317.62%	-46.54%	-36.46%	11/9/2026 (Estimated)
IMCR Immunocore	-$35.51M	-$0.37	N/A	111.28	N/A	-4.20%	-4.54%	-1.66%	11/5/2026 (Estimated)
MAZE Maze Therapeutics	-$131.12M	-$2.52	N/A	N/A	N/A	N/A	-34.94%	-30.18%	N/A
RARE Ultragenyx Pharmaceutical	-$575M	-$5.84	N/A	N/A	N/A	-81.79%	N/A	-44.40%	11/3/2026 (Estimated)

Latest ARCT, RARE, IMCR, and MAZE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	ARCT Arcturus Therapeutics	-$0.6866	N/A	N/A	N/A	$8.00 million	N/A
11/5/2026	Q3 2026	IMCR Immunocore	-$0.1204	N/A	N/A	N/A	$152.86 million	N/A
11/3/2026	Q3 2026	RARE Ultragenyx Pharmaceutical	-$0.9274	N/A	N/A	N/A	$182.62 million	N/A
8/11/2026	Q2 2026	MAZE Maze Therapeutics	-$0.76	-$0.76	N/A	-$0.76	N/A	N/A
8/7/2026	Q2 2026	ARCT Arcturus Therapeutics	-$0.9964	-$0.84	+$0.1564	-$0.84	$3.11 million	$2.96 million
8/7/2026	Q2 2026	IMCR Immunocore	-$0.01	-$0.02	-$0.01	-$0.02	$148.57 million	N/A
8/4/2026	Q2 2026	RARE Ultragenyx Pharmaceutical	-$1.22	-$0.90	+$0.32	-$0.90	$183.08 million	$214.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
MAZE Maze Therapeutics	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	5.88	5.88
IMCR Immunocore	0.94	4.47	4.44
MAZE Maze Therapeutics	0.09	18.31	18.31
RARE Ultragenyx Pharmaceutical	N/A	1.73	1.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
IMCR Immunocore	84.50%
MAZE Maze Therapeutics	N/A
RARE Ultragenyx Pharmaceutical	97.67%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	17.80%
IMCR Immunocore	10.10%
MAZE Maze Therapeutics	5.30%
RARE Ultragenyx Pharmaceutical	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	111	28.42 million	23.36 million	Optionable
IMCR Immunocore	524	51.50 million	46.30 million	Optionable
MAZE Maze Therapeutics	141	55.55 million	52.61 million	N/A
RARE Ultragenyx Pharmaceutical	1,371	98.59 million	93.46 million	Optionable

ARCT, RARE, IMCR, and MAZE Headlines

Recent News About These Companies

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Purchase Disclosed by Rep. Gilbert Ray Cisneros, Jr.

1 hour ago | marketbeat.com

Ultragenyx Pharmaceutical (RARE) Receives a Hold from RBC Capital

October 10, 2026 | theglobeandmail.com

Pharmaceutical Executive Daily: Ultragenyx Sells Rare Pediatric Disease Priority Review Voucher

October 8, 2026 | pharmexec.comP

Is Ultragenyx Pharmaceutical (RARE) Undervalued Following EMA Validation For Its Sanfilippo Gene Therapy?

October 8, 2026 | finance.yahoo.com

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash

October 8, 2026 | zacks.com

Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

October 7, 2026 | marketscreener.comM

Ultragenyx To Sell Rare Pediatric Disease Voucher For $210 Mln

October 7, 2026 | rttnews.com

Ultragenyx lands $210M deal to sell FDA priority review voucher – Retail sees 'huge' buying opportunity

October 7, 2026 | msn.com

Ultragenyx to sell FDA priority review voucher for $210M

October 7, 2026 | seekingalpha.com

Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million

October 7, 2026 | proactiveinvestors.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Jumps 3.9% - Here's Why

October 7, 2026 | marketbeat.com

Ultragenyx Monetizes FDA Priority Review Voucher Asset

October 7, 2026 | tipranks.com

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

October 7, 2026 | globenewswire.com

Ultragenyx (RARE) EMA Validation of MPS IIIA Gene Therapy: Inflection Point or Incremental Milestone?

October 7, 2026 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

October 6, 2026 | globenewswire.com

Comparing Ultragenyx Pharmaceutical (NASDAQ:RARE) & Mereo BioPharma Group (NASDAQ:MREO)

October 6, 2026 | americanbankingnews.com

Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation

October 5, 2026 | zacks.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Down 6% - Should You Sell?

October 5, 2026 | americanbankingnews.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 6% - Here's Why

October 5, 2026 | marketbeat.com

Gene therapy for rare lysosomal storage disorder nabs FDA approval

October 5, 2026 | nature.comN

Ultragenyx Pharmaceutical | Science & Technology

October 3, 2026 | note.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ARCT, RARE, IMCR, and MAZE Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$12.03 -0.58 (-4.60%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$12.02 -0.01 (-0.12%)

As of 10/13/2026 07:56 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Immunocore NASDAQ:IMCR

$27.82 -1.22 (-4.20%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$27.90 +0.07 (+0.27%)

As of 10/13/2026 07:39 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Maze Therapeutics NASDAQ:MAZE

$26.66 -1.04 (-3.75%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$26.00 -0.66 (-2.48%)

As of 10/13/2026 07:30 PM Eastern

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is to bring novel precision medicines to patients to maximize our impact on human health. CKD is a serious, progressive condition that affects approximately 37 million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated with reduced disease burden and improved kidney function in distinct groups of CKD patients. Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant that underpins our therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the clinical setting. In October 2024, we reported results for our Phase 1 clinical trial of MZE829, in which we enrolled 111 healthy patients who received either single or multiple ascending doses of 20 mg to 480 mg of MZE829 administered daily. Treatment was well tolerated with no severe adverse events or serious adverse events reported in patients treated with single doses up to 480 mg and multiple doses of up to 350 mg daily for seven days. Dose-proportional pharmacokinetics, or PK, was observed with low variability (10-40%) across doses. We initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose our first patient in the first quarter of 2025 and to report proof of concept data in the first quarter of 2026. Our second lead program, MZE782, is an oral, small molecule inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today’s standard of care. We initiated a Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025. In addition to CKD, we believe MZE782 may provide benefit to patients suffering from the genetically defined metabolic disease, phenylketonuria, or PKU. Following our ongoing Phase 1 trial of MZE782, we plan to conduct a parallel Phase 2 clinical trial to explore MZE782 as a potential treatment of PKU. Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug development. We believe the process of variant functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us apart from others in the field. We were incorporated under the laws of the State of Delaware on August 29, 2017, originally under the name Genetic Modifiers NewCo, Inc. We changed our name on July 5, 2018 to Modulus Therapeutics, Inc. and on September 25, 2018, to Maze Therapeutics, Inc. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.

Ultragenyx Pharmaceutical NASDAQ:RARE

$14.92 -0.38 (-2.48%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$15.00 +0.08 (+0.54%)

As of 10/13/2026 07:55 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARCT, RARE, IMCR, and MAZE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARCT, RARE, IMCR, and MAZE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARCT, RARE, IMCR, and MAZE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ARCT, RARE, IMCR, and MAZE Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

Immunocore NASDAQ:IMCR

Maze Therapeutics NASDAQ:MAZE

Ultragenyx Pharmaceutical NASDAQ:RARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARCT, RARE, IMCR, and MAZE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARCT, RARE, IMCR, and MAZE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARCT, RARE, IMCR, and MAZE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ARCT, RARE, IMCR, and MAZE Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

Immunocore NASDAQ:IMCR

Maze Therapeutics NASDAQ:MAZE

Ultragenyx Pharmaceutical NASDAQ:RARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools